A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis

NCT07270003

Status	RECRUITING
Phase	Not Applicable
Sponsor	Xijing Hospital
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (1)

- e18years old; clinically/pathologically confirmed PPP; failure/intolerance to e1 conventional systemic therapy (12-24 weeks of standard dosing); physician-judged suitability for ivarmacitinib; signed informed consent.

Exclusion (1)

- Lymphocyte count \<0.5×10y/L, neutrophils \<1×10y/L, platelets \<100×10y/L, or hemoglobin \<80g/L; serum creatinine \>132.6 μmol/L, AST/ALT \>2×ULN, or total bilirubin \>2.0mg/dL; active infections (tuberculosis, hepatitis B/C, systemic candidiasis); other conditions hindering participation or data interpretation.

Locations (1 total)

Xijing hospital, Xi'an, Shaanxi, China